Display Settings:

Format

Send to:

Choose Destination
Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):701-5.

The feasibility of a randomized clinical perinatal trial: maternal magnesium sulfate for the prevention of cerebral palsy.

Author information

  • 1Department of Obstetrics and Gynecology, University of Alabama at Birmingham, USA.

Abstract

OBJECTIVE:

Because recent epidemiologic data suggest an association between maternal magnesium sulfate use and a decreased risk of cerebral palsy in infants who survive preterm birth, we investigated the feasibility of a randomized trial of intrapartum maternally administered magnesium sulfate to prevent cerebral palsy in children who were born before term.

STUDY DESIGN:

On the basis of a literature review, we calculated cumulative rates of delivery, neonatal survival, and cerebral palsy for progressively longer gestational age intervals beginning at 24 weeks' gestation. Sample size estimates with two-tailed chi 2 tests without Yates' correction (alpha = 0.05, beta = 0.2, 50% effect size) for a clinical trial were calculated for these rates.

RESULTS:

In the 4-week interval from 24 weeks 0 days to 27 weeks 6 days the minimum number of neonates required to conduct a randomized trial would be 1189. Loss to follow-up of neonates, maternal ineligibility, and failure of enrollment would substantially increase the number of necessary gravid women delivered in the 4-week interval to complete such a trial, such that 1 million pregnancies would be required to generate the necessary number of eligible gravid women. Shorter gestational age intervals (e.g., 24 weeks 0 days to 25 weeks 6 days) required fewer neonates (n = 729) but more pregnancies (n = 1.5 million). Because of the decreasing prevalence of cerebral palsy at higher gestational ages, extending the gestational age interval (e.g., to 29 weeks 6 days) markedly increased the minimum number of neonates to 1982 but only slightly decreased the necessary number of pregnancies, to 900,000.

CONCLUSIONS:

A randomized trial of maternally administered intrapartum magnesium sulfate to reduce the rate of cerebral palsy in surviving preterm neonates would be a formidable undertaking, requiring a concerted multicentered effort.

PMID:
8828437
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk